These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8603027)

  • 1. Unmaintained cytogenetic and molecular remission in chronic myelogenous leukaemia following treatment by interferon.
    Rio B; Ramond S; Lacorte JM; Pépin D; Barbu V; Viguie F; Ajchenbaum-Cymbalista F; Lorrot M; Chambaz J; Zittoun R
    Br J Haematol; 1996 Feb; 92(2):504-5. PubMed ID: 8603027
    [No Abstract]   [Full Text] [Related]  

  • 2. BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha.
    Reiter A; Marley SB; Hochhaus A; Sohal J; Raanani P; Hehlmann R; Gordon MY; Goldman JM; Cross NC
    Br J Haematol; 1998 Sep; 102(5):1271-8. PubMed ID: 9753056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity.
    Kurzrock R; Estrov Z; Kantarjian H; Talpaz M
    J Clin Oncol; 1998 Apr; 16(4):1526-31. PubMed ID: 9552062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
    Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
    J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of BCR/ABL mRNA-expressing bone-marrow cells in patients with chronic myelogenous leukemia in complete cytogenetic remission induced by interferon-alpha therapy.
    Eberlé F; Toiron Y; Camerlo J; Lafage M; Sainty D; Arnoulet C; Raineri V; Gabert J; Maraninchi D; Mannoni P
    Leuk Lymphoma; 1995 Jun; 18(1-2):153-7. PubMed ID: 8580818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alfa-2a interferon induces molecular remission in post-BMT relapse of chronic myelogenous leukaemia. Report of a case with loss of bcr-abl RNA].
    Casado LF; Steegmann JL; Picó M; Requena MJ; Gómez C; Fernández-Rañada JM
    Sangre (Barc); 1995 Oct; 40(5):417-20. PubMed ID: 8553177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor leucocyte infusions for relapse in chronic myelogenous leukaemia.
    Kumar L
    Lancet; 1994 Oct; 344(8930):1101-2. PubMed ID: 7934489
    [No Abstract]   [Full Text] [Related]  

  • 8. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
    Hochhaus A; Lin F; Reiter A; Skladny H; van Rhee F; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Br J Haematol; 1995 Sep; 91(1):126-31. PubMed ID: 7577619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myelogenous leukemia: does interferon alpha prolong life?
    Hehlmann R
    Leukemia; 1996 Feb; 10(2):193-6. PubMed ID: 8637225
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolonged hematological remission by mitoxantrone and interferon--alpha-2b in a child with resistant Philadelphia chromosome-positive chronic myelogenous leukemia.
    Duru F; Tuncer M; Hiçsönmez G
    Eur J Haematol; 1993 Sep; 51(3):173-4. PubMed ID: 8405332
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preliminary results of interferon alpha treatment for patients with chronic myelogenous leukemia].
    Popławska-Szczygłowska L; Starzyńska J; Chmarzyńska-Mróz E
    Pol Tyg Lek; 1996 May; 51(19-22):283-4. PubMed ID: 9289711
    [No Abstract]   [Full Text] [Related]  

  • 13. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged survival and probable cure in chronic myelogenous leukemia.
    Gabor EP
    Am J Hematol; 1995 Oct; 50(2):149. PubMed ID: 7572999
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia.
    Kloke O; Niederle N; Qiu JY; Wandl U; Moritz T; Nagel-Hiemke M; Hawig I; Opalka B; Seeber S; Becher R
    Br J Haematol; 1993 Mar; 83(3):399-403. PubMed ID: 8485045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of interferon in the treatment of chronic myelogenous leukemia in chronic phase.
    Guilhot F
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S39-46. PubMed ID: 8177714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
    Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman PS; Ku S; Gutterman JU; Talpaz M
    Leukemia; 1992 Aug; 6(8):754-60. PubMed ID: 1640725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durable molecular complete remission induced by low-dose imatinib plus low-dose interferon alpha in a patient with chronic myelogenous leukaemia.
    Takeuchi J; Miura K; Hatta Y; Sawada U
    J Int Med Res; 2006; 34(1):103-8. PubMed ID: 16604830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
    Armenta D; Espallargas C; Paz A; Rodríguez Martorel J; Ladines R; Alvarez C; Román J; Andrés P
    Sangre (Barc); 1996 Dec; 41(6):465-7. PubMed ID: 9148424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.